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Abstract. The article is dedicated to the research of legal and management aspects of intellectual property rights protection in the field of 
medicine and biotechnologies. The authors clarified the patenting peculiarities of inventions in the area of medicine and biotechnologies, 
particularly issues concerning applications for obtaining patents, the determination of intellectual property compliance with patentability 
requirements, the registration of granted patents in the relevant registry etc. They identified the legal and organizational aspects of 
intellectual property rights protection in the field of medicine and biotechnologies upon the study of the leading European countries 
experience (using the examples of the United Kingdom, Germany and France). One summarized the international experience in the 
protection of intellectual property rights in the field of medicine and biotechnologies and highlighted the regulation specifics of these 
issues according to the current Ukrainian legislation. In particular, the authors defined the requirements for the protection of intellectual 
property rights in the field of medicine and biotechnologies, which have been set out in legal documents at the international level.
Recommendations for management organization and intellectual brand capital protection depending on specificity of national economic 
and legal model. Are offered. The mechanism of economic security management of a country for intellectual property right protection in 
the field of medicine and biotechnologies is created.
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1. Introduction 
Nowadays, in the presence of fleeting globalization processes, the world system of intellectual property rights 
protection is almost formed (Sagiyeva et al, 2018; Zeibote et al., 2019; Chehabeddine, Tvaronavičienė, 2020; 
Lincényi, Čársky, 2020; Danko et al, 2020). This means that, in many countries around the world the efforts of 
governments to protect intellectual property rights are aimed at creating regulatory framework, which would 
offer guarantees and effective mechanisms for such protection. The significance of intellectual property rights 
protection matter is explained by the fact that, in the light of global development, the economics intellectu-
alization process takes place. In the end, such a phenomenon influences the economic security of a particular 
country.
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The world trends of economic and technological development require the adjustment of legislation, that is to 
say, bringing laws and other regulatory instruments in line with world requirements and standarts in the sphere 
of intellectual property rights protection. With the ratification of the Ukraine-EU Association Agreement in 
2014 our State made a commitment to approximate national legal system to EU legislation in the field of in-
tellectual property. Therefore, to define strategic goals in reforming of intellectual property field became top 
priority. In this context, the subject matter of intellectual property rights protection in the field of medicine and 
biotechnologies is not an exception, and that is why it needs more detailed research. 
2. Literature Survey
In order to study the features of intellectual property rights protection in the field of medicine and biotechnolo-
gies, it is appropriate to analyze the experience of leading European countries on their governments’ regulation 
of such issues, as well as legal and organizational aspects of providing this protection. It is important to clarify 
that, intellectual property rights protection in most of the countries is carried out by means of patenting inven-
tions in this area. For this purpose, patent laws and regulations of a particular country are applied.
This way, the key provisions of patent law in the United Kingdom are stated in The Patents Act, which was 
adopted back in 1977. In the branch of medicine and biotechnologies, an element isolated from the human body 
or otherwise produced by means of technical process, including the sequence or partial sequence of a gene, may 
constitute a patentable invention, even if the structure of that element is identical to that of a natural element. 
However, the law clearly states that, the application for such a patent must necessarily reveal the industrial use 
of the sequence or partial sequence of a gene. Any person may apply for a patent either alone or jointly with 
another. Each patent application is made in the prescribed form and filed at the Patent Office in the prescribed 
manner. It also provides for the payment of patent fee. As soos as it is possible after the patent has been granted, 
the controller will publish a notice in the journal about its issuance, the specification of the patent, as well as 
names of the owner and the inventor (if they are different), and any other information concerning the patent, 
which the controller deems appropriate to publish. The patent is valid for 20 years, starting from the date of fil-
ing the application for the patent or another date, which may be prescribed (The Patents Act, 1977). Enshrined 
in The Patents Act of 1977, the general principles of patenting have been specified in The Patents Rules of 2007 
and, therefore, defined the detailed patenting procedures.
The main official government body, responsible for legal protection of inventions in the United Kingdom is The 
Intellectual Property Office (IPO), which is subordinated to the Department for Business, Innovation & Skills 
(BIS). The IPO is regulated by The Patents Act of 1977 and The Patents Rules of 2007 in its work. In addition, 
15 Patent Library Centres are located in the United Kingdom to provide addressing a variety of intellectual 
property issues (UK PatLib contact information).
The issues of legal protection of intellectual property in Germany are regulated by two main legal acts: The Pat-
ents Act (Patentgesetz (PatG)) of 1980 and The Patent Costs Act (Patentkostengesetz (PatKostG)) of 2001. The 
Patents Act defines the list of objects protected by patents, the procedure for obtaining patents, along with the 
structure and functions of the Patent Office and the Patent Court. The patent is valid for 20 years starting from 
the day, which follows the application date. It is important to note the restrictions on the granting of patents for 
inventions set by Section 2 of The Patents Act. No patents shall be granted for inventions, the commercial ex-
ploitation of which would be contrary to public order or morality. In particular, patents shall not be granted for:
- processes for cloning human beings;
- processes for modifying the germ line genetic identity of human beings;
- uses of human embryos for industrial or commercial purposes;
- processes for modifying the genetic identity of animals, which are likely to cause them suffering without any 
substantial medical benefit to man or animal, and also animals resulting from such processes (Patentgesetz 
(PatG), 1980).
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The Patent Office is an independent supreme federal authority within the Federal Ministry of Justice and Con-
sumer Protection. The Patent Office is composed of the President and other members, appointed for life. The 
Patent Office contains the examiner’s offices, which process patent applications and inform about the status of 
their examination, as well as patent agencies for all the issues, related to the granting of patents and legal as-
sistance in case of disputes (Patentgesetz (PatG), 1980).
The legislation of France, which regulates the issues of the legal protection of intellectual property rights, 
including the field of medicine and biotechnologies, has been codified and presented by The Intellectual Prop-
erty Code (Code de la propriété intellectuelle) of 1992. The peculiar feature of current French patent laws is 
that, they distinguish the regulation of biotechnological products from the regulation of traditional inventions. 
Art.611-18 of The Code determines the fact that, the human body at the various stages of its formation and 
development, along with the simple discovery of one of its elements, including complete or partial sequence 
of a gene, cannot constitute patentable inventions. Only that invention, which is a technical use of the function 
of human body element, may be protected by patent. This protection covers only the element of human body 
to the extent, necessary for the implementation and harnessing of this particular application. This should be 
specifically and accurately explained in the patent application. In particular, the following are not patentable: 
а) processes for cloning human beings; b) procedures for modifying the genetic identity of humans; c) uses of 
human embryos for industrial or commercial purposes; d) complete or partial sequence of a gene per se (Code 
de la propriété intellectuelle, 1992).
The legal body responsible for granting patents for inventions is The National Institute of Industrial Property 
(L’Institut national de la propriété industrielle (INAPI)), which is under authority of the Ministry of Economy, 
Industry and Digital Technologies. INAPI implements the national policy on industrial property; facilitates 
public acess to technical data about all the documents and information concerning their sphere of examina-
tion; assists, develops and enhances inventive and innovative abilities with the help of both material and moral 
incentives. Beside the regulations of The Intellectual Property Code, the legal basis of INAPI’s work for the 
protection of intellectual property rights in the field of medicine and biotechnologies is constituted by:
- The Regulation № 03-07 on patents for the invention of 2003;
- The Executive Decree № 05-275, which determines the procedure of filing applications and granting patents 
for the invention of 2005;
- The Executive Decree № 76-121 on Procedures for Registration and Publication of Geographical Indications 
and the Establishment of the Relevant Fees of 1976 (The official website of the L’Institut national de la pro-
priété industrielle, INAPI).
3. Methods
The research of the legal and organizational aspects of intellectual property rights protection in the field of 
medicine and biotechnologies was performed using epistemological method, system-structural method, and 
comparative law-based analysis.
The epistemological method of research made it possible to find out the peculiarities of patenting inventions in 
the field of medicine and biotechnologies. That is, in particular, ones concerning patent applications, the confir-
mation of intellectual property compliance with patentability requirements, the registration of granted patents 
in the relevant registry, etc. 
Upon the study of the leading European countries experience (using the examples of the United Kingdom, Ger-
many, France) due to the system-structural method of research one defined legal and organizational aspects of 
intellectual property rights protection in the field of medicine and biotechnologies.
The comparative law-based analysis was applied to summarize the international experience in protection of 
intellectual property rights in the field of medicine and biotechnologies, as well as to highlight the regulation 
specifics of these issues in accordance with the current Ukrainian legislation. This method was likewise used to 
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identify requirements for the protection of intellectual property rights in the field of medicine and biotechnolo-
gies, which are laid down in international legal documents, as well as the peculiarities of international organiza-
tions activities, the function of which relates to the protection of intellectual property rights in the research area.
4. Results
The protection of intellectual property rights in the field of medicine and biotechnologies at the international 
level is carried out in accordance with the requirements of regulatory legal documents. Special attention should 
be paid to the provisions of the Convention on Biological Diversity of 1992; the European Patent Convention of 
1973; the Directive 1998/44/EC of the European Parliament and of the Council of 1998 on the legal protection 
of biotechnological inventions; the Convention for the protection of Human Rights and Dignity of the Human 
Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine 
of 1997; The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) of 1994 between the 
member nations of the World Trade Organization.
The definition of the term «biotechnology» first found its regulation in the Convention on Biological Diversity, 
and therefore, was enshrined in the legal document at the international level. Art. 2 explains biotechnology as 
any technological application that uses biological systems, living organisms or derivatives thereof, to make or 
modify products or processes for specific use (Convention on Biological Diversity, 1992).
According to the European Union law the legal protection of intellectual property in the field of biotechnologies is 
implemented by means of patenting inventions in this area. The relevant provisions of the Directive 98/44/EC of 
the European Parliament and of the Council of 1998 on the legal protection of biotechnological inventions confirm 
this fact. Art. 1 of the Directive 98/44/EC obliges EU member states to protect biotechnological inventions under 
national patent law. However, if necessary, EU member states have a right to adjust their national patent law to take 
account of the provisions of the Directive 98/44/EC. Art. 3 of the Directive 98/44/EC defines the requirements for 
patenting new inventions. In particular, it is noted, that inventions which are new, which involve an inventive step 
and, which are susceptible of industrial application shall be patentable. Even if they concern a product consisting 
of or containing biological material or a process by means of which biological material is produced, processed or 
used. Plant and animal varieties, as well as essentially biological processes for the production of plants and ani-
mals, shall not be patentable, as indicated in Art. 4 of the Directive 98/44/EC (Directive 98/44/EC, 1998).
According to the Directive 98/44/EC, human organism, at the various stages of its formation and development, 
and the simple discovery of one of its elements, including the sequence or partial sequence of a gene, cannot 
constitute patentable inventions. On the other hand, an element isolated from the human body or otherwise 
produced by means of a technical process, including the sequence or partial sequence of a gene, may constitute 
a patentable invention, even if the structure of that element is identical to that of a natural element (Directive 
98/44/EC, 1998). Thus, the provisions of the Directive 98/44/EC differentiated intellectual property objects into 
patentable ones and those, which cannot constitute patentable inventions because of some particular features.
The specific peculiarities of intellectual property protection in the field of biotechnologies by means of patents 
are given in Chapter II of the Directive 98/44/EC. The protection conferred by a patent on a biological material 
possessing specific characteristics as a result of the invention shall extend to any biological material derived 
from that biological material through propagation or multiplication in an identical or divergent form and pos-
sessing those same characteristics (Directive 98/44/EC, 1998).
The European Patent Convention of 1973 defined patentable objects of intellectual property. As to the intellec-
tual property rights protection in the field of medicine and biotechnologies, the following should be mentioned: 
according to Art. 53 of the Convention, European patents are not granted for 1) plant or animal varieties and 
essentially biological processes for the production of plants and animal; 2) methods for treatment of the human 
or animal body by surgery or therapy, and diagnostic methods practised on the human or animal body (European 
Patent Convention, 1973).
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The Convention for the protection of Human Rights and Dignity of the Human Being with regard to the Ap-
plication of Biology and Medicine: Convention on Human Rights and Biomedicine of 1997 states that, any 
health-related intervention, including scientific research, may only take place in accordance with corresponding 
professional duties and standarts (Convention on Human Rights and Biomedicine, 1997).
The World Trade Organization (WTO) (membership of Ukraine since 2008) is guided by the legal document, 
which regulates the issues of intellectual property rights protection in the field of medicine and biotechnologies, 
and that is - the Agreement of Trade-Related Aspects of Intellectual Property Rights (TRIPS). TRIPS entitles 
members to exclude from patentability inventions, the prevention within their territory of the commercial ex-
ploitation of which is necessary to protect ordre public or morality, including the security of human, animal 
or plant life and health or to avoid serious prejudice to the environment (part 2 Art. 27 TRIPS). Along with 
that member nations of TRIPS may also prohibit patenting certain forms of life (plants and animals), but they 
shall provide patent protection of specific plant varieties, micro-organisms, non-biological and microbiological 
processes (parag. b part 3 Art. 27 TRIPS) (WTO: Agreement of Trade-Related Aspects of Intellectual Property 
Rights, 1994).
The international organizations dealing with the protection of intellectual property rights are The World Intel-
lectual Property Organization (WIPO), the European Patent Office (EPO) and the European Union Intellectual 
Property Office (EUIPO).
The World Intellectual Property Organization (WIPO) is an international intergovernmental organization, cre-
ated in accordance with the Convention adopted in 1967 by member states of the Paris Union for the Protection 
of Industrial Property, the Berne Union for the Protection of Literary and Artistic Works, and other special un-
ions. The International Bureau of WIPO (the Secretariat) has been located in Geneva since 1974, when WIPO 
acquired the status of the Specialized agency of the United Nations (The official website of WIPO). 
The European Patent Office (EPO) is ingovernmental body, which works under the legal basis of the European 
Patent Convention. From 16 member states, who signed The European Patent Convention of 1973, the organiza-
tion has grown up to 38 members, including all 28 member states of the EU plus such states as Norway, Switzer-
land and Turkey. EPO studies European patent applications, thereby giving a chance to all inventors, researchers 
and companies worldwide to protect their inventions in almost 44 countries by means of a centralized and single 
patent grant procedure, which involves a simplified procedure – filing only one application. EPO performs the 
search and thorough examinations of constantly growing number of European patent applications and inter-
national patent applications, filed in line with the Patent Cooperation Treaty. The disclosure of invention and 
subsequent publication are fundamental for the European patent system. The European Publication Server is a 
source, where the public can get the official copies of European patent documents. The European Patent Register 
provides detailed procedural information on all patent applications (The official website of the EPO).
Among many different types of patents, EPO also issues biotechnological patents. Biotechnology is explained 
as the use of biological processes, organisms, or systems to manufacture products intended to improve the qual-
ity of human life. Inventors have been filing applications for biotechnology patents for over a hundred years. 
Biotechnology is an important industrial sector for the European economy, providing employment and growth 
for European society and countless useful medical and other products for its citizens. It covers a vast field rang-
ing from medical and pharmaceutical products (55% of all patents in biotechnology) to industrial processes 
(41%) and agriculture, which comprises just 4%. (Biotechnology patents at the EPO).
Patents are crucial for promoting medical progress. Advances in the life sciences and pharmaceutical sector 
have had an impact on life expectancy and the quality of life. That is explained by the fact, that most modern 
medicines are based on biotechnologies. One of the earliest biomedicaments was insulin, a life-saving drug 
for diabetics. Other patented medical inventions have provided breakthroughs in DNA fingerprinting, paternity 
testing and blood transfusions, where patented tests to check donated blood for the presence of deadly viruses 
have improved patient safety. Many anti-cancer drugs based on patented human gene sequences are prolonging 
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the lives of cancer patients. Governments can counter a perceived abuse of a patent monopoly by, for example, 
granting a compulsory licence against a patent holder to enable generics companies to sell the same product more 
cheaply, negotiating with patent holders to reduce the price of patented medicines, and using competition laws. 
Patents are an effective barrier to illicit copying of medicines and the health risks. Patents constitute a limited 
exclusive right only: once the patent has expired (after a maximum of 20 years), the invention falls in the public 
domain and can be used by anyone without paying royalties. National authorities work with pharmaceutical 
companies to negotiate lower prices for medical products, and after the patent has expired, cheaper generic 
copies may enter the market. The patent system also creates transparency: patent applications are published 18 
months after filing, so they disclose detailed information about the latest technical improvements. Like plants, 
animals are patentable according to the law. The patent applications filed with the EPO mostly concern trans-
genic (genetically modified) mice and rats used in medical research. However, the EPO takes ethical considera-
tions into account: if the transgenic invention is found to make the animal suffer, it may only be patented if it 
brings a substantial medical benefit to humans (or animals) (Biotechnology patents at the EPO).
On March 15, 2019 the Eurasian Patent Office (EAPO) announced the signing of collaborative agreement with 
the Medicines Patent Pool (MPP) on accessing the legal status patent information of the Eurasian patent ap-
plications and granted Eurasian patents for pharmaceutical inventions. The aim of this cooperation is to enable 
interested parties to carry out their activities in developing or supplying medicines to the market without violat-
ing the rights of owners of Eurasian patents. 
It is worth to mention, that The European Union Intellectual Property Office (EUIPO), known as OHIM until 
March 23, 2016, is operating to provide the protection of intellectual property rights throughout the EU. EUIPO 
administers the EU Trade Mark and Design rights, and since 2012 has also been responsible for the Observatory 
on the Infringement of Intellectual Property Rights and the Orphan Works Database. EUIPO works closely with 
the European Patent Office (EPO) and the World Intellectual Property Organisation (WIPO), as well as with 
another representative offices dealing with intellectual property matters in the EU and international partners 
to develop suggestions for the use of trade mark and design registration experience in Europe and worldwide. 
EUIPO is a decentralized EU Agency, which constantly cooperates with the European Commission and its 
Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (GROW). EUIPO has legal, 
administrative and financial autonomy over staffing and budgetary matters. EUIPO is governed by the Manage-
ment Board and Budget Committee, comprising:
- 1 representative per EU country;
- 1 representative from the European Parliament;
- 2 representatives from the European Commission (The official website of the EUIPO).
Apart from international organizations WIPO, EPO and EUIPO, which protect intellectual property rights in 
the field of medicine and biotechnologies by means of granting patents, there also exists the Unified Patent 
Court (UPC), where one can apply in case of violation of these rights. UPC, established on February 19, 2013, 
has exclusive jurisdiction over litigation on the infringement and the invalidation (revocation) of European pat-
ents and EU unitary patents, as well as litigation on the infringement and the validity of supplementary protec-
tion certificates – documents, certified on basis of the Regulation (EC) № 469/2009 of the European Parliament 
and of the Council of May 6, 2009 concerning the supplementary protection certificate for medicinal products 
or the Regulation (EC) № 1610/96 of the European Parliament and of the Council of July 23, 1996 concern-
ing the creation of a supplementary protection certificate for plant protection products. The legal framework 
of UPC functioning is presented in the Agreement on a Unified Patent Court, according to which the Court has 
exclusive competence in respect of:
(a) actions for actual or threatened infringements of patents and supplementary protection certificates and re-
lated defences, including counterclaims concerning licences;
(b) actions for declarations of non-infringement of patents and supplementary protection certificates;
(c) actions for provisional and protective measures and injunctions;
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(d) actions for revocation of patents and for declaration of invalidity of supplementary protection certificates;
(e) counterclaims for revocation of patents and for declaration of invalidity of supplementary protection cer-
tificates;
(f) actions for damages or compensation derived from the provisional protection conferred by a published Eu-
ropean patent application;
(g) actions relating to the use of the invention prior to the granting of the patent or to the right based on prior 
use of the invention;
(h) actions for compensation for licences;
(i) actions concerning decisions of the European Patent Office (Agreement on a Unified Patent Court, 2013).
One of the key elements in the Ukraine–EU Association Agreement of 2014 was the security and protection of 
intellectual property rights, including the field of medicine and biotechnologies. The key principles of coopera-
tion in this area are set out in Chapter 9, Title IV, «Intellectual Property». Art. 221 defined the main rule, ac-
cording to which the protection of biotechnological inventions is implemented by parties under national patent 
law. However, if necessary, they may adjust their patent law to take account of the provisions of the Agreement.
Serious attention needs to be paid to defining the patentability of intellectual property objects in the field of 
medicine and biotechnologies. Inventions, which concern plants or animals shall be therefore patentable if 
their technical feasibility is not confined to a particular plant or animal variety. Inventions shall be considered 
unpatentable if their commercial exploitation is contrary to ordre public (public order) or public morality. The 
following shall be considered unpatentable:
а) processes for cloning human beings;
b) processes for modifying the germ line genetic identity of human beings;
c) uses of human embryos for industrial or commercial purposes;
d) processes for modifying the genetic identity of animals, which are likely to cause them suffering without 
any substantial medical benefit to man or animal, and also animals resulting from such processes (Association 
Agreement, 2014).
The protection conferred by a patent on a biological material possessing specific characteristics as a result of 
an invention shall extend to any biological material derived from that biological material through propagation 
or multiplication in an identical or divergent form and possessing those same characteristics. The protection 
conferred by a patent on a process that enables a biological material possessing specific characteristics to be 
produced as a result of an invention shall extend to biological material directly obtained through that process 
and to any other biological material derived from the directly obtained biological material through propagation 
or multiplication in an identical or divergent form and possessing those same characteristics. The protection 
conferred by a patent on a product containing or consisting of genetic information shall extend to all material 
(Association Agreement, 2014).
The Agreement also defines cases when cross-licensing is compulsory. They are, in particular:
а) where a breeder cannot acquire or exploit a plant variety right without infringing a prior patent, he/she may 
apply for a compulsory licence for non-exclusive use of the invention protected by the patent inasmuch as the 
licence is necessary for the exploitation of the plant variety to be protected, subject to payment of an appro-
priate royalty. The parties shall provide that, where such a licence is granted, the holder of the patent will be 
entitled to a cross-licence on reasonable terms to use the protected variety;
b) where the holder of a patent concerning a biotechnological invention cannot exploit it without infringing a 
prior plant variety right, he/she may apply for a compulsory licence for non-exclusive use of the plant variety 
protected by that right, subject to payment of an appropriate royalty. The parties shall provide that, where such 
a licence is granted, the holder of the variety right will be entitled to a cross-licence on reasonable terms to use 
the protected invention.
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Applicants for the licences referred to in paragraph 11 of this Article must demonstrate that:
а) they have applied unsuccessfully to the holder of the patent or of the plant variety right to obtain a contractual 
licence;
b) the plant variety or the invention constitutes significant technical progress of considerable economic inter-
est compared with the invention claimed in the patent or the protected plant variety (Association Agreement, 
2014).
Thus, under the current Ukraine–EU Association Agreement, the protection of intellectual property in the field 
of medicine and biotechnologies needs harmonization of the national legislation with the requirements of the 
EU law. At the same time, bringing Ukrainian patent law system of intellectual property protection up to the 
European standarts demands taking into account the interests of both biotechnology and health care providers, 
and society as a whole.
A detailed investigation of the legal international and national ensuring intellectual property protection requires 
development of an effective mechanism for economic security management of a country in order to protect 
intellectual property rights. Such a mechanism in the area of medicine and biotechnology should be formed 
according to the concept of the precisely brand capital management. The value of intellectual property for 
economic and legal security of a country is revealed in the process of its instrumental use. A well-known trade 
mark in the field of medicine and biotechnology does not appear and, most importantly, does not exist in itself, 
it requires purposeful continuous management (Malhotra, Y. 2003): 
(1) It is a management tool with the help of which public authorities actively influence all stakeholders (cus-
tomers, partners, business community) creating a certain image of a company and its products and desired 
behaviour of the mentioned individuals in relation to a company. In this sense a trade mark is a tool to achieve 
state strategic development goals.
(2) A mark is an object of management in relation to which generally accepted stages and procedures of man-
agement are applied – goal-setting, choice of strategy, evaluation of management effectiveness, etc. The elabo-
ration of brand capital management methods for the development of economic security should be based on the 
study of component features of a managed object-trade marks. Being guided by a systematic approach, it is 
possible to formulate the main conceptual principles of organizational and economic mechanism formation of 
brand capital management:
1. The integrity of organizational and economic mechanism of brand capital management in which the func-
tioning of all its parts (subsystems) and elements is directed to a general goal achievement which faces a sys-
tem. In management this feature of a system is reflected in the following:
a) when there is a general unified target function of brand capital management which reflects the purpose facing 
a system, a target private function should be integrated for each part of a system;
b) the criteria of efficiency of a subsystem and elements functioning should maximally match the criteria of 
efficiency of a system in generfal (Bontis, Nick, 2001).
Accordingly, if there is the main unified target function which is separate from intellectual property objects, a 
target (private) function of each attribute should be also unified though a private goal achievement relating to 
each attribute should ensure implementation of the main target function of intellectual property objects. The 
complexity of an organizational and economic mechanism of brand capital management which lies in the fact 
that a change in any of its parts causes changes in other parts of it which are linked via a set of feedbacks (Dro-
byazko, et. al. 2019). For example, disadvantages in an advertising company organization lead to a decrease in 
sales volume and reduction in market share which can cause a rise in the product unite price in order to keep 
gross income in a prior volume.
Preservation at the present time and in prospect of a creative dominant role of a person in organizational and 
economic mechanism of brand capital management and necessity in this case to create moral and material inter-
est in the result of system functioning. Continuity of development of organizational and economic mechanism 
JOURNAL OF SECURITY AND SUSTAINABILITY ISSUES
ISSN 2029-7017 print/ISSN 2029-7025 online
27
of brand capital management. Interchangeability of ways to promote intellectual property objects. Influence of 
public authorities on brand intellectual capital through the levers of economic and socio-psychological manage-
ment methods is presented in Fig. 1.
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Figure 1. Mechanism of economic security management of a country for intellectual property  
rights protection in the area of medicine and biotechnologies
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As the problem of formation of cross-cutting efficiency criterion of brand capital management also refers to the 
problem of management of both a particular mark and brand capital in general, it is necessary to enumerate the 
approaches to studying and matching the criteria at all levels of public management.
1) The problem of a general criterion. In order to achive the optimum in a multi-brand business, it is required to 
have an indicator by which it is possible to determine the optimal development option or (as a last resort) some 
scale of advantages of possible development plans for specific trade marks.
2) Problems of a local criterion. The assessment of management of a particular brand should meet the the inter-
ests of the whole system to the maximum extent possible. Therefore, it is necessary to determine such a local 
criterion of optimality (if a cross-cutting one is missing) which would meet the general business interests of a 
company to the maximum possible extent.
3) Problems of multistage optimization. Particular ways of matching general and local solutions are required. 
Taking in to account the complexity of a brand capital management system (if a cross-cutting criterion is miss-
ing) such coordination is still possible only using a multistage (hierarchical) approach to optimization processes 
through development of iterative algorithms for linking solutions of different levels (Sullivan, P., 2000).
Being based on these methodical approaches, it is possible to formulagte a scientifically sound definition of 
the perfect position for economic security management in the field of intellectual brand capital. The model of 
perfect position of intellectual brand capital in the system of economic security of a country can be given in a 
form of a Fig. 2.
Perfect position of  
intellectual brand capital
Absolute consumer’s belief 
in unique advantages of 




Conviction in the mistake  
of consumers who have made 
their choice in favor  
of another TM
Perception of a TM as 
a necessary attribute of life
Fanatical commitment  
to a TМ
Perception of a TM as  
an irriplaceable vital value
Deep feeling of spiritual unity 
with other consumers who 
have chosen the given TM
An irresistible sense of duty  
to convince other individuals 
of the correct choice  
of the given TM
Figure 2. Model of a perfect position of intellectual brand capital positioning
A perfect position of intellectual brand capital is such its perception in an economic and legal system of a 
country in which an owner of a mark is absolutely sure of unique advantages of intellectual brand capital over 
other marks, the given brand is connected only with positive associations and it is percievd as an irreplaceable 
value and necessary attribute of life; perception in which a consumer is a fanatical supporter of this brand, is 
fully convinced that consumers who purchase goods of other marks make a wrong choice, considers it to be his 
duty to recommend the given brand to other consumers and feels spiritual unity with the consumers who have 
chosen the particular brand (Choo, C.W. and Nick Bontis, 2002). 
On the basis of concept of perfect positioning of intellectual brand captal, its effectiveness can be evaluated as 
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a degree of achievement of a perfect state of position parameters of intellectual property objects, that is, if we 
take a number of all buyers of intellectual property as 100%, a graphical model of a perfect position of intel-

















Figure 3. Graphical model of a perfect position of intellectual brand capital  
in the system of economic security of a country
where , , , , , , , , ,  – are parameters of a position of intellectual property objects includ-
ing:
 – is a share (percentage) of market entities who are absolutely sure of the unique advantages of the given 
mark of intellectual property objects over other marks;
 – is a share (percentage) of market entities who have only positive associations with the particular mark;
 – is a share (percentage) of market entities who are fanatically commited to the given brand;
 – is a share (percentage) of market entities who perceive a mark as an irreplaceable life value;
 – is a share (percentage) of market entities who perceive a brand as a necessary attribute of life; 
 – is a share (percentage) of market entities who are completely convinced that the consumers who buy goods 
of other marks make a wrong choice;
 – is a share (percentage) of market entities who consider it to be their duty to recommend the particular mark 
to other consumers;
 – is a share (percentage) of market entities who feel spiritual unity with the consumers who have chosen the 
given brand.
Then the absolute effectiveness of positioning of intellectual property objects can be represented by such a 
formula (1):
    
     (1)
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where  – is a value of the i parameter of an intellectual property object position (in proportions of its perfect 
state);
 – is a coefficient of significance of the i parameter of an intellectual property object position;
 = from 0 to 1 
 
∑ ia  = 1.
Values  are set according to the expert opinion.
 – is set through conducting appropriate sociological researches.
Relying on benchmarking methodology, it will be more objectively to assess effectiveness of positioning on 
intellectual property objects in comparison with the indicators of a market brand-leader or brand-main com-
petitor. In this case it is possible to calculate the relative efficiency of intellectual property object positioning:





EPBEPB = ,     (2)
where 
 




rEPB  >1 –the efficiency of intellectual property object positioning is higher than the efficiency of intellec-
tual brand capital positioning- the strongest competitor.
Taking account of the costs on intellectual property object promotion:








= / ,    (3)
where Z and Zk  –comparative costs on economic and legal security assurance respectively.
While studying the efficiency of positioning in a long-term period, it is important to assess the given indicators 
in dynamics for which the corresponding coefficients can be calculated:
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EPBk  –are coefficients of dynamics of relative efficiency of intellectual property object positioning 
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on economic and legal security assurance during an accounting 
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Thus, the positioning of intellectual brand capital is a process of perception management of intellectual prop-
erty objects by economic entities and legal system of a country the purpose of which is: 
a) convincing a consumer of unique advantages of the given mark of intellectual property objects over other 
marks; b) formation of consumer’s exclusively positive associations with the particular trade mark; c) forma-
tion of consumer’s sense of irreplaceability and vital necessity of a given mark; d) formation of fanatical devo-
tion to the brand; e) fostering a sense of duty to recommend a given mark to other consumers; f) fostering a 
sense of spiritual unity with the consumers who have chosen this particular brand; g) formation of consumer’s 
belief thatg other consumers, who purchase goods of other marks, make the wrong choice.
In 2015 the Decree of the President of Ukraine № 5/2015 adopted the Sustainable Development Strategy 
«Ukraine 2020». The Strategy has envisaged the implementation of 62 state reforms and programmes in four 
development directions. The reform of intellectual property protection must be implemented under the direc-
tion of security (Sustainable Development Strategy «Ukraine 2020», 2015). In our opinion, carrying out the in-
tellectual property protection reform according to the mentioned security direction is not a coincidence. Indeed, 
the intellectualization of economy has a significant impact on the economic security of a particular country, 
which ultimately affects the position of the state in the global space (Reznik et al., 2020).
Like in most European countries, the intellectual property rights protection in the field of medicine and bio-
technologies in Ukraine is implemented by means of patenting inventions in this field. In particular, the current 
Ukrainian legislation has got The Law of Ukraine «On Protection of Rights to Inventions and Utility Models» 
of 1993. According to Art. 1 of the Law, invention is understood to be a result of intellectual activity of a human 
being in any field of technology. Patent is a protective document confirming priority, authorship and ownership 
right for invention. Patent for an invention is understood as a type of patent issued as a result of the qualifica-
tion expert appraisal of the application for patent. In Ukraine the validity term of an invention patent is 20 years 
starting from the date of filing. Invention meets patentability requirements if it is new, has an inventive standard 
and is industrially applicable (Law of Ukraine № 3687-XII, 1993).
In Ukraine the procedure of granting patents for inventions is performed by the Institution in the field of legal 
protection of invention rights, that is, the State Enterprise «Ukrainian Intellectual Property Institute» (herein-
after referred to as Institution). If a person desires to obtain a patent and has a right for it, he/she shall submit 
an application to the Institution. The expert appraisal of an application has the status of scientific and technical 
examination. It consists of preliminary examination, the formal expert appraisal and, on the application for a 
patent, the qualification expert appraisal. The final results of the expert appraisal of the application, which is not 
deemed revoked and is not revoked, are presented in a substantiated conclusion of examination, which enters 
into force upon approval by the Institution. On the basis of such conclusion the Institution makes a decision to 
grant a patent or to refuse such patent. The decision of the Institution is sent to the applicant. From the date of 
the receipt of an application by the Institution and till the publication of the information on the application or 
the publication of the information on the issue of a patent, the materials of the application shall be treated as 
confidential information. On the basis of the decision to issue a patent the state registration of the patent takes 
place. For this purpose the appropriate information is entered into the Register. The form of the Register and 
the Register keeping procedure are determined by the Institution. The state registration of the patent for an in-
vention is carried out upon condition that documents confirming the payment of the patent issue fee and fee for 
publication of the information on the issue of a patent are received. These fees should be payed after applicant 
receives a decision about granting a patent. Upon entering the information in the Register, any person shall have 
the right to familiarise himself with it (Law of Ukraine № 3687-XII, 1993).
5. Discussion
Like in most European countries, the intellectual property rights protection in the field of medicine and bio-
technologies in Ukraine is implemented by means of patenting inventions in this area. At the level of national 
legislation the patenting issues are regulated by The Law of Ukraine «On Protection of Rights to Inventions 
and Utility Models». 
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In accordance with the signed Ukraine–EU Association Agreement of 2014, the security and protection of intel-
lectual property rights, including the field of medicine and biotechnologies, became one of the key elements. 
Thus, under the current Ukraine–EU Association Agreement, the protection of intellectual property in the field 
of medicine and biotechnologies needs harmonization of the national legislation with the requirements of the 
EU law. At the same time, bringing Ukrainian patent law system of intellectual property protection up to the 
European standarts demands taking into account the interests of both biotechnology and health care providers, 
and society as a whole. In the context of the research question, we consider the experience of France to be a 
positive example, as long as its legistation concerning the legal protection of intellectual property rights, in-
cluding the field of medicine and biotechnologies, has been codified and presented by The Intellectual Property 
Code. It must be acknowledged, that Ukrainian law in the field of intellectual property is represented by a large 
number of laws and by-law regulatory acts, while some issues are even regulated by separate rules of the codes. 
In this case, it appears to be relevant and substantial to establish a single codified legal act, the rules of which 
will regulate intellectual property issues in many areas.
Conclusions
Within the investigated subject matter one highlighted the peculiarities of intellectual property rights protec-
tion in the field of medicine and biotechnologies by studying the experience of the leading European countries 
concerning their government regulation of such issues, as well as legal and organizational aspects providing 
this protection. In particular, it was found out, that in the United Kingdom the key principles of patenting in-
ventions are stated in The Patents Act of 1977 and specified in The Patents Rules of 2007, which define the de-
tailed patenting procedures. The main official government body responsible for legal protection of inventions 
in the United Kingdom is The Intellectual Property Office (IPO), which is subordinated to the Department for 
Business, Innovation & Skills (BIS). The issues of legal protection of intellectual property in Germany are 
regulated by two main legal acts: The Patents Act of 1980 and The Patent Costs Act of 2001. The intellectual 
property rights issues in the field of medicine and biotechnologies are under control of The Patent Office, 
which is an independent supreme federal authority within the Federal Ministry of Justice and Consumer Pro-
tection. The legislation of France, which regulates the issues of the legal protection of intellectual property 
rights, including the field of medicine and biotechnologies, is presented by The Intellectual Property Code of 
1992, The Regulation № 03-07 on patents for the invention of 2003; The Executive Decree № 05-275, which 
determines the procedure of filing applications and granting patents for the invention of 2005; The Executive 
Decree № 76-121 on Procedures for Registration and Publication of Geographical Indications and the Estab-
lishment of the Relevant Fees of 1976. The legal body responsible for granting patents for inventions is The 
National Institute of Industrial Property, which is under authority of the Ministry of Economy, Industry and 
Digital Technologies.
The protection of intellectual property rights in the field of medicine and biotechnologies at the international 
level is carried out in accordance with the requirements of regulatory legal documents, among which are: the 
Convention on Biological Diversity of 1992; the European Patent Convention of 1973; the Directive 1998/44/
EC of the European Parliament and of the Council of 1998 on the legal protection of biotechnological inven-
tions; the Convention for the protection of Human Rights and Dignity of the Human Being with regard to the 
Application of Biology and Medicine: Convention on Human Rights and Biomedicine of 1997; The Agreement 
on Trade-Related Aspects of Intellectual Property Rights (TRIPS) of 1994 between the members of the World 
Trade Organization. The international organizations dealing with the protection of intellectual property rights 
are The World Intellectual Property Organization (WIPO), the European Patent Office (EPO) and the European 
Union Intellectual Property Office (EUIPO).
Like in most European countries, the intellectual property rights protection in the field of medicine and biotech-
nologies in Ukraine is also implemented by means of patenting inventions in this area. In particular, the current 
Ukrainian legislation has got The Law of Ukraine «On Protection of Rights to Inventions and Utility Models» 
of 1993. The procedure of granting patents for inventions is performed by the Institution in the field of legal 
protection of invention rights, that is, the State Enterprise «Ukrainian Intellectual Property Institute».
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Therefore, the integration of intellectual capital management system into the current system of economic and 
legal security of a country, will allow to implement the principles of systematic approach to management and 
intellectual property protection, to optimize public management resources for the formation and change of legal 
framework in the field of intellectual property. There will be an opportunity to promptly monitor the effective-
ness of brand capital use which will ensure the increase in the level of national legal discipline and strengthen-
ing economic and legal security.
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